000			04150 am a22006613u 4500
042			_adc
700	1	0	_aHerrington, William G. _eauthor _92196
700	1	0	_aStaplin, Natalie _eauthor _92197
700	1	0	_aWanner, Christoph _eauthor _92198
700	1	0	_aGreen, Jennifer B. _eauthor _92199
700	1	0	_aHauske, Sibylle J. _eauthor _92200
700	1	0	_aEmberson, Jonathan R. _eauthor _92201
700	1	0	_aPreiss, David _eauthor _92202
700	1	0	_aJudge, Parminder _eauthor _92203
700	1	0	_aMayne, Kaitlin J. _eauthor _92204
700	1	0	_aNg, Sarah Y.A. _eauthor _92205
700	1	0	_aSammons, Emily _eauthor _92206
700	1	0	_aZhu, Doreen _eauthor _92207
700	1	0	_aHill, Michael _eauthor _92208
700	1	0	_aStevens, Will _eauthor _92209
700	1	0	_aWallendszus, Karl _eauthor _92210
700	1	0	_aBrenner, Susanne _eauthor _92211
700	1	0	_aCheung, Alfred K. _eauthor _92212
700	1	0	_aLiu, Zhi-Hong _eauthor _92213
700	1	0	_aLi, Jing _eauthor _92214
700	1	0	_aHooi, Lai Seong _eauthor _92215
700	1	0	_aLiu, Wen _eauthor _92216
700	1	0	_aKadowaki, Takashi _eauthor _92217
700	1	0	_aNangaku, Masaomi _eauthor _92218
700	1	0	_aLevin, Adeera _eauthor _92219
700	1	0	_aCherney, David _eauthor _92220
700	1	0	_aMaggioni, Aldo P. _eauthor _92221
700	1	0	_aPontremoli, Roberto _eauthor _92222
700	1	0	_aDeo, Rajat _eauthor _92223
700	1	0	_aGoto, Shinya _eauthor _92224
700	1	0	_aRossello, Xavier _eauthor _92225
700	1	0	_aTuttle, Katherine R. _eauthor _92226
700	1	0	_aSteubl, Dominik _eauthor _92227
700	1	0	_aPetrini, Michaela _eauthor _92228
700	1	0	_aMassey, Dan _eauthor _92229
700	1	0	_aEilbracht, Jens _eauthor _92230
700	1	0	_aBrueckmann, Martina _eauthor _92231
700	1	0	_aLandray, Martin J. _eauthor _92232
700	1	0	_aBaigent, Colin _eauthor _92233
700	1	0	_aHaynes, Richard _eauthor _92234
245	0	0	_aEmpagliflozin in Patients with Chronic Kidney Disease
260			_c2023-01-12.
500			_a/pmc/articles/PMC7614055/
500			_a/pubmed/36331190
520			_aBACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligibility required an estimated glomerular filtration rate (eGFR) of ≥20 to <45 ml/minute/1.73m(2); or ≥45 to <90 ml/minute/1.73m(2) with a urinary albumin-to-creatinine ratio (ACR) of ≥200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR <10 ml/minute/1.73m(2), a sustained decline in eGFR of ≥40%, or a renal death) or death from cardiovascular causes. RESULTS: During a median of 2.0 years follow-up, a primary outcome event occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% CI 0.64 to 0.82; P<0.001), with consistent results in those with or without diabetes and across the range of eGFR studied. There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003), but no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%), or death from any cause (4.5% vs 5.1%). The rates of serious adverse events were broadly similar in the two groups. CONCLUSIONS: Empagliflozin reduced the risk of the composite outcome of kidney disease progression or cardiovascular death in a wide range of patients at risk of CKD progression. (Funding:Boehringer Ingelheim, Eli Lilly and others; Clinicaltrials.gov:NCT03594110, EuDRACT: 2017-002971-24).
540			_a
540			_ahttps://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a CC BY-ND 4.0 (https://creativecommons.org/licenses/by-nd/4.0/) International license.
546			_aen
690			_aArticle
655	7		_aText _2local
786	0		_nN Engl J Med
856	4	1	_uhttp://dx.doi.org/10.1056/NEJMoa2204233 _zConnect to this object online.
999			_c887 _d887